Search

Displaying results 8731 - 8740 of 10000 in total
  1. Drug

    Lerociclib

    go.drugbank.com/drugs/DB16218
    Investigational

    Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast

  2. Drug

    Abitesartan

    go.drugbank.com/drugs/DB19863
    Experimental

    Abitesartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Abitesartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

  3. Drug

    Tunicamycin

    go.drugbank.com/drugs/DB13172
    Experimental

    Tunicamycin blocks N-linked glycosylation (N-glycans) resulting in cell cycle arrest at the G1 phase in human cells. It is used as an experimental tool to induce unfolded protein response. … One member of this family is the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first

  4. Drug

    Exbivirumab

    go.drugbank.com/drugs/DB17747
    Experimental

    It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202] … Exbivirumab is an investigational monoclonal antibody.

  5. Drug

    Lunsekimig

    go.drugbank.com/drugs/DB19009
    Investigational

    Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).

  6. Drug

    Technetium Tc-99m epratuzumab

    go.drugbank.com/drugs/DB15452
    Experimental

    Technetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).

  7. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738] … NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9.

  8. Drug

    1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline

    go.drugbank.com/drugs/DB08555
    Experimental

    This medication is known to target mitogen-activated protein kinase 10. … 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline is a solid. This compound belongs to the isoquinolines and derivatives.

  9. Drug

    Pecavaptan

    go.drugbank.com/drugs/DB16279
    Investigational

    Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).

  10. Drug

    Vamikibart

    go.drugbank.com/drugs/DB18896
    Investigational

    Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).